Business
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced that it will report financial results for the first quarter ended March 31, 2026, after market close on Thursday, May 14, 2026.
About this update from Valion Bio, Inc.
[{"type":"text","content":"SAN ANTONIO, Texas, May 11, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced that it will report financial results for the first quarter ended March 31, 2026, after market close on Thursday, May 14, 2026.","length":399,"tagName":"p"},{"type":"image","alt":"VALION BIO, INC (PRNewsfoto/Valion Bio, Inc.)","displaySize":"","headline":null,"caption":"VALION BIO, INC (PRNewsfoto/Valion Bio, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/6a1c19825a3562d437f1cb371710ca86"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OFWQFJvnfWBH7yFC1odhhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNQ--/https://media.zenfs.com/en/prnewswire.com/6a1c19825a3562d437f1cb371710ca86","width":400,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/VgvUJ.uCTODLXXC3bhg1bA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MA--/https://media.zenfs.com/en/prnewswire.com/6a1c19825a3562d437f1cb371710ca86","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2972189/Valion_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Management will host a conference call and webcast to discuss the Company's financial results and provide a business update.","length":128,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast Details","length":35,"tagName":"p"},{"type":"text","content":"Webcast: https://www.webcaster5.com/Webcast/Page/2865/54024Dial-In: 888-506-0062International: 973-528-0011Participant Access Code: 118764","length":141,"tagName":"p"},{"type":"text","content":"A replay of the webcast will be available on the Investors section of the Company's website following the conclusion of the event.","length":134,"tagName":"p"},{"type":"text","content":"About Valion Bio, Inc.","length":22,"tagName":"p"},{"type":"text","content":"Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO) is a clinical-stage immunotherapeutics company developing Entolimod™, a TLR5 agonist, for Acute Radiation Syndrome (ARS), oncology supportive care, and longevity indications. Entolimod™ for ARS has received Fast Track and Or...